AstraZeneca India receives CDSCO approval for Durvalumab for specified additional indication Read more
AbbVie’s $10.1 bn Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge: GlobalData Read more
AstraZeneca’s Durvalumab gets CDSCO nod to treat locally advanced or metastatic biliary tract cancer Read more
Bristol Myers Squibb get EC approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with chemotherapy for metastatic NSCLC Read more